论文部分内容阅读
目的:探讨稳心颗粒联合索他洛尔治疗心律失常患者的疗效及对患者血浆血管紧张素Ⅱ(Ang Ⅱ)、C反应蛋白(CRP)和氨基端脑钠肽前体(NT-proBNP)水平的影响。方法:选取台州市中心医院2018年1月至2019年10月收治的心律失常患者162例，按照随机数字表法分为观察组(81例)与对照组(81例)。对照组患者给予索他洛尔治疗，观察组在对照组基础上联合稳心颗粒治疗。两组疗程均为2个月。比较两组临床疗效，治疗前后心功能、Ang Ⅱ、CRP和NT-proBNP水平变化及不良反应。结果:观察组总有效率(92.59%，75/81)高于对照组(77.78%，63/81)(χn 2＝7.044，n P<0.05)。观察组治疗后左室舒张末期内径(LVEDD)(53.18±3.09)mm、左室收缩末期内径(LVESD)(52.19±2.35)mm，均低于对照组的(58.97±2.73)mm、(57.79±2.65)mm，而每搏心输出量(SV)(76.93±3.67)mL、左室射血分数(LVEF)(53.90±2.64)%，均高于对照组的(71.35±2.87)mL、(46.75±2.18)%(n t＝12.638、14.230、10.779、18.795，均n P<0.05)。观察组治疗后血浆Ang Ⅱ(96.52±12.16)ng/L、CRP(4.30±0.69)mg/L和NT-proBNP(394.25±47.15)ng/L，均低于对照组的(135.42±23.15)ng/L、(6.27±0.78)mg/L和(565.29±56.72)ng/L(n t＝13.389、17.025、20.870，均n P<0.05)。观察组不良反应发生率为11.11%(9/81)，低于对照组的30.86%(25/81)(χn 2＝9.529，n P<0.05)。n 结论:稳心颗粒联合索他洛尔治疗心律失常患者疗效显著，可降低血浆Ang Ⅱ、CRP和NT-proBNP水平，改善心功能，且不良反应发生率低。“,”Objective:To investigate the therapeutic effect of Wenxin granule combined with sotalol on patients with arrhythmia and its influence on the levels of plasma angiotensin Ⅱ(Ang Ⅱ), C-reactive protein (CRP) and NT-proBNP.Methods:From January 2018 to October 2019, 162 patients with arrhythmia admitted to Taizhou Central Hospital were divided into observation group (81 cases) and control group (81 cases) according to the random digital table method.The control group was treated with sotalol, and the observation group was treated with Wenxin granule on the basis of the control group.The course of treatment in both two groups was 2 months.The changes of cardiac function, Ang Ⅱ, CRP and NT-proBNP levels, as well as adverse reactions were compared before and after treatment.Results:The total effective rate of the observation group (92.59%, 75/81) was higher than that of the control group (77.78%, 63/81) (χn 2=7.044, n P<0.05). After treatment, the LVEDD [(53.18±3.09)mm] and LVESD [(52.19±2.35)mm] in the observation group were lower than those in the control group [(58.97±2.73)mm and (57.79±2.65)mm], while the SV [(76.93±3.67)mL] and LVEF [(53.90±2.64)%] in the observation group were higher than those in the control group [(71.35±2.87)mL and (46.75±2.18)%], the differences were statistically significant (n t=12.638, 14.230, 10.779, 18.795, all n P<0.05). The plasma AngⅡ [(96.52±12.16)ng/L], CRP [(4.30±0.69)mg/L] and NT-proBNP [(394.25±47.15)ng/L] in the observation group were lower than those in the control group [(135.42±23.15)ng/L, (6.27±0.78)mg/L and (565.29±56.72)ng/L] (n t=13.389, 17.025, 20.870, all n P<0.05). The incidence of adverse reactions in the observation group (11.11%) was lower than that in the control group (30.86%) (χn 2=9.529, n P<0.05).n Conclusion:Wenxin granule combined with sotalol is effective in the treatment of arrhythmia, which can reduce the plasma levels of Ang Ⅱ, CRP and NT-proBNP, improve the heart function and has no obvious adverse reactions.